CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
CytomX Therapeutics (CTMX) Tops Q2 EPS by 17c
August 8, 2023 4:29 PM EDTCytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.02), $0.17 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $13.68 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
... More